KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 0.28.

  • Nektar Therapeutics' Equity Ratio rose 7788.01% to 0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.28, marking a year-over-year increase of 7788.01%. This contributed to the annual value of 0.2 for FY2024, which is 3925.86% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Equity Ratio stood at 0.28, which was up 7788.01% from 0.12 recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Equity Ratio high stood at 0.68 for Q1 2021, and its period low was 0.12 during Q2 2025.
  • For the 5-year period, Nektar Therapeutics' Equity Ratio averaged around 0.39, with its median value being 0.4 (2023).
  • Data for Nektar Therapeutics' Equity Ratio shows a peak YoY increase of 7788.01% (in 2025) and a maximum YoY decrease of 15026.29% (in 2025) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Equity Ratio (Quarter) stood at 0.61 in 2021, then decreased by 15.17% to 0.52 in 2022, then plummeted by 36.22% to 0.33 in 2023, then tumbled by 39.26% to 0.2 in 2024, then surged by 41.25% to 0.28 in 2025.
  • Its Equity Ratio stands at 0.28 for Q3 2025, versus 0.12 for Q2 2025 and 0.05 for Q1 2025.